Home   Drug Development   CRO Services   Newsroom   About ReceptoPharm   Contact
» Recent News
» Archives
» E-Alerts
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More


Nutra Pharma Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain
October 07, 2009

Nyloxin Rx, which was developed by Nutra Pharma’s drug discovery subsidiary, ReceptoPharm, is a prescription medicine launching in late-2009 for the treatment of severe (Stage 3) chronic pain.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.

Nyloxin Rx is a prescription pain reliever produced by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating Stage 3 pain, which is the most severe pain that inhibits one’s ability to fully function. Additionally, Nyloxin Rx does not rely on the use of opioids for its pain relieving action, but, instead, uses a novel mechanism from cobra venom peptides for treating pain.

“For the past 10 years, we have allocated significant time and resources to the study of peptides from cobra venom for the treatment of several indications, including pain,” explained Dr. Paul Reid, CEO of ReceptoPharm. “Given the amount of clinical evidence using cobra venom as a pain reliever, the drug’s well-defined safety profile, and the active pharmaceutical ingredient, which is a monographed drug under United States Homeopathic Pharmacopoeia, we plan to go directly to market with Nyloxin Rx and begin introducing it to physicians later this year,” he added.

According to a report published by IMS Health, there were a total of 237 million U.S. opioid prescriptions in 2008 with over 85 million prescriptions specifically for the treatment of chronic pain. Additionally, a December 2008 article in the Journal Gazette reported that sales of Oxycodone (not including Percodan) totaled $2.89 billion and that sales of Fentanyl totaled $1.55 billion from January to October of the same year.

“We are excited to be launching Nyloxin Rx as a prescription pain reliever at a time when both physicians and patients are actively looking for alternatives to opioid-based pain therapies. We are confident that Nyloxin Rx will compete successfully with other prescription pain medicines and become the preferred treatment for severe chronic pain,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “While we continue to focus on bringing Nyloxin Rx to market, we are also planning to use our financial and strategic resources to begin additional human clinical trials in the near-term for our other drug indications outside of pain,” he concluded.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Introducing Nyloxin Rx for the treatment of severe (Stage 3) chronic pain should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Recent News
November 05, 2010
Nutra Pharma Awarded Grant under the Qualifying Therapeutic Discovery Project Program
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name: